Effect of topiramate or carbamazepine on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in healthy obese and nonobese female subjects

被引:112
|
作者
Doose, DR
Wang, SS
Padmanabhan, M
Schwabe, S
Jacobs, D
Bialer, T
机构
[1] Hebrew Univ Jerusalem, Dept Pharmaceut, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[2] Hebrew Univ Jerusalem, David R Bloom Ctr Pharm, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel
[3] Johnson & Johnson Pharmaceut Res & Dev LLC, Raritan, NJ USA
关键词
topiramate; carbamazepine; ethinyl estradiol; norethidrone; obesity;
D O I
10.1046/j.1528-1157.2003.55602.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Purpose: To study the pharmacokinetics of a combination oral contraceptive (OC) containing norethindrone and ethinyl estradiol during OC monotherapy, concomitant OC and topiramate (TPM) therapy, and concomitant OC and carbamazepine (CBZ) therapy in order to comparatively evaluate the pharmacokinetic interaction, which may cause contraceptive failure. Methods: This randomized, open-label, five-group study included two 28-day cycles. Five groups of female subjects received oral doses of ORTHO-NOVUM 1/35 alone (cycle 1) and then concomitant with TPM or CBZ (cycle 2). The treatment groups were group 1, TPM, 50 mg/day; group 2, TPM, 100 mg/day; group 3, TPM, 200 mg/day; group 4, TPM, 200 mg/day (obese women); and group 5, CBZ, 600 mg/day. Group 4 comprised obese women whose body mass index (BMI) was between 30 and 35 kg/m(2). The BMI of the remaining four groups was less than or equal to27 kg/m(2). Results: Coadministration of TPM at daily doses of 50, 100, and 200 mg (nonobese) and 200 mg (obese) nonsignificantly (p > 0.05) changed the mean area under the curve (AUC) of ethinyl estradiol by -12%, +5%, -11%, and -9%, respectively, compared with OC monotherapy. A similar nonsignificant difference was observed with the plasma levels and AUC values of norethindrone (p > 0.05). CBZ (600 mg/day) significantly (p < 0.05) decreased the AUC values of norethindrone and ethinyl estradiol by 58% and 42%, respectively, and increased their respective oral clearance by 69% and 127% (p < 0.05). Because CBZ induces CYP 3A-mediated and glucuronide conjugation metabolic pathways, the significant increase in the oral clearance of ethinyl estradiol and norethindrone was anticipated. Conclusions: TPM, at daily doses of 50-200 mg, does not interact with an OC containing norethindrone and ethinyl estradiol. The lack of the TPM-OC interaction is notable when it is compared with the CBZ-OC interaction.
引用
收藏
页码:540 / 549
页数:10
相关论文
共 50 条
  • [1] Effect of topiramate on the pharmacokinetics of an oral contraceptive containing norethindrone and ethinyl estradiol in patients with epilepsy
    Rosenfeld, WE
    Doose, DR
    Walker, SA
    Nayak, RK
    EPILEPSIA, 1997, 38 (03) : 317 - 323
  • [2] EFFECT OF MULTIPLE DOSES OF ISAVUCONAZOLE ON THE PHARMACOKINETICS OF ORAL CONTRACEPTIVE WITH ETHINYL ESTRADIOL AND NORETHINDRONE IN HEALTHY SUBJECTS
    Townsend, R.
    Yamazaki, T.
    Kowalski, D.
    Lademacher, C.
    Pearlman, H.
    Rammelsberg, D.
    Desai, A.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S90 - S91
  • [3] BMS-790052 HAS NO EFFECT ON THE PHARMACOKINETICS OF A COMBINED ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND NORGESTIMATE IN HEALTHY FEMALE SUBJECTS
    Bifano, Marc
    Sevinsky, Heather
    Persson, A.
    Hwang, Carey
    Kandoussi, Hamza
    Jiang, Hao
    Grasela, Dennis M.
    Bertz, Richard J.
    HEPATOLOGY, 2011, 54 : 991A - 992A
  • [4] Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women
    Griffith, SG
    Dai, YQ
    CLINICAL THERAPEUTICS, 2004, 26 (12) : 2056 - 2065
  • [5] LACK OF EFFECT OF GABAPENTIN ON THE PHARMACOKINETICS OF A NORETHINDRONE ACETATE ETHINYL ESTRADIOL-CONTAINING ORAL-CONTRACEPTIVE
    ELDON, MA
    UNDERWOOD, BA
    RANDINITIS, EJ
    POSVAR, EL
    SEDMAN, AJ
    NEUROLOGY, 1993, 43 (04) : A307 - A308
  • [6] The Effects of Ambrisentan on the Pharmacokinetics of the Oral Contraceptive Components Ethinyl Estradiol and Norethindrone
    Spence, R. A.
    Mandagere, A.
    Dufton, C.
    Boinpally, R.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2009, 179
  • [7] Pharmacokinetics of Oral Combination Contraceptive Drugs Containing Ethinyl Estradiol and Levonorgestrel in Healthy Female Chinese Volunteers
    Xin, X.
    Wu, Y.
    Liu, X.
    Sun, C.
    Geng, T.
    Ding, L.
    DRUG RESEARCH, 2016, 66 (02) : 100 - 106
  • [8] The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women
    Zhang, Jenny
    Chung, Ellen
    Yones, Cynthia
    Persson, Anna
    Mahnke, Lisa
    Eley, Timothy
    Xu, Xiaohui
    Bertz, Richard
    ANTIVIRAL THERAPY, 2011, 16 (02) : 157 - 164
  • [9] EFFECT OF SAXAGLIPTIN ON THE PHARMACOKINETICS OF ACTIVE COMPONENTS OF ORTHO-CYCLEN®, A COMBINED ORAL CONTRACEPTIVE CONTAINING ETHINYL ESTRADIOL AND NORGESTIMATE, IN HEALTHY FEMALE SUBJECTS.
    Upreti, Vijay V.
    Hsiang, Bonnie B.
    Li, Li
    Nam, Su
    Xu, Xiaohui
    LaCreta, Frank P.
    Boulton, David W.
    JOURNAL OF CLINICAL PHARMACOLOGY, 2010, 50 (09): : 1063 - 1063
  • [10] BIOEQUIVALENCE OF 2 ORAL-CONTRACEPTIVE DRUGS CONTAINING NORETHINDRONE AND ETHINYL ESTRADIOL
    SAPERSTEIN, S
    EDGREN, RA
    LEE, GJL
    JUNG, D
    FRATIS, A
    KUSHINSKY, S
    MROSZCZAK, E
    DORR, A
    CONTRACEPTION, 1989, 40 (05) : 581 - 590